Track topics on Twitter Track topics that are important to you
NICE draft guidance says that Tecentriq in combination with chemotherapy is not cost effective in untreated advanced triple-n...
Original Article: England’s NICE Rejects Tecentriq In Triple-Negative Breast CancerNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...